VivoSeq
Other

Estrogen

1

Pipeline Programs

5

Active Trials

1

Companies Involved

Estrogen is an early-stage landscape with 1 program across 1 company. The most active players are Pfizer. 1 therapy is approved.

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Trial Status

47

clinical trials

Completed32 · 68%
Unknown status5 · 11%
Recruiting4 · 9%
Withdrawn3 · 6%
Terminated2 · 4%
Active, not recruiting1 · 2%

Trial Activity

47 trials

Cardiac Outcomes With Near-Complete Estrogen Deprivation
Recruiting··N/A·NCT05309655·90 enrolled
Role of Estrogen on Skeletal Outcomes in FHA
Recruiting·UUniversity of Virginia·Phase 2·NCT07010146·150 enrolled
Impact of Estrogen on Fear Extinction R61
Completed·NNYU Langone Health·Phase 1·NCT02673606·136 enrolled
Estrogen Hormone Protocol
Completed·National Institute on Aging (NIA)·Phase 3·NCT00000177·120 enrolled
Effects of Acute Estrogen Therapy on Bone Formation
Completed·MMayo Clinic·Phase 1·NCT02349113·20 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)